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synchronous delivery of docetaxel and TUBB3
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Bioresponsive nanoparticles (NPs) are of interest for anticancer nanomedicines, owing to the possibility to
‘design in’ selective modulation of drug release at target sites. Here we describe the double emulsion for-
mulation of redox-responsive NPs based on modified polyethylene glycol (PEG)-co-poly(lactic-co-glyco-
lic acid) (PLGA) block copolymers and oligo (β-aminoesters) (OBAE), both of which contained disulfide lin-
kages, for the co-delivery of a cytotoxic small molecule drug and a nucleic acid. In particular, we focused
our attention on docetaxel (DTX) and a siRNA against TUBB3, a gene that encodes for βIII-tubulin, in
order to have a synergistic effect in the treatment of lung cancer. Spherical NPs of around 150 nm with
negative zeta potential and high loading efficiencies of both drugs were obtained. Stability and release
studies showed “on demand” drug release under reducing conditions. Unloaded NPs containing PEG-
disulfide-PLGA and OBAE were well-tolerated by lung cancer cells, thus masking the intrinsic cytotoxicity
of OBAE, while for intracellular siRNA delivery, redox responsive NPs demonstrated a higher cell internal-
ization with a preferential cytoplasmic accumulation of siRNA, with a subsequent fast gene-silencing
efficiency. The viability of cells treated with combined DTX/TUBB3-siRNA NPs significantly decreased as
compared to NPs loaded only with DTX, thus showing an efficient combined anticancer effect, due to a
substantial reduction of β-tubulin expression. Finally, in an in vivo feasibility study employing an orthotopic
lung cancer model, NPs formulated with an anti-luciferase siRNA distributed throughout the lungs follow-
ing oro-tracheal administration, and demonstrated effective gene knockdown and no apparent cyto-
toxicity. Taken together, these results show that the double emulsion formulated redox responsive
PEG-PLGA and OBAE systems represent a promising new therapeutic approach for the local combined
chemo- and gene-therapy of lung cancer.
Introduction
Lung cancer (LC) is one of the most common cancers world-
wide and non-small cell lung cancer (NSCLC) accounts for
approximately 85% of all LC cases.1 The simultaneous admin-
istration of two or more conventional anticancer drugs rep-
resents the first-line treatment for these patients, but the
development of multidrug resistance (MDR) strongly limits the
therapeutic effectiveness. Therefore, combinations of multiple
therapeutic modalities (e.g. chemotherapy, gene therapy,
immunotherapy, photodynamic therapy) with additive/syner-
gistic mechanisms of cell killing are becoming standard in
clinical settings for combating resistance mechanisms.2,3 In
particular, regulation of gene expression through RNA-inter-
ference based therapeutics is currently of interest, due to the
ability of these molecules to silence specific pathways involved
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
d1nr02179f
aDivision of Molecular Therapeutics and Formulation, School of Pharmacy,
University of Nottingham, NG7 2RD, UK. E-mail: claudia.conte@unina.it,
cameron.alexander@nottingham.ac.uk
bDrug Delivery Laboratory, Department of Pharmacy, University of Napoli Federico II,
80131 Napoli, Italy
cThe BioDiscovery Institute and Faculty of Medicine & Health Sciences, University of
Nottingham, NG7 2RD, UK
dChildren’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney,
NSW 2052, Australia
eARC Centre of Excellence in Convergent Bio-Nano Science and Technology and
Australian Centre for NanoMedicine, UNSW Sydney, NSW 2052, Australia
fSchool of Women’s and Children’s Health, Faculty of Medicine, UNSW Sydney, NSW,
Australia 2052

























































































in MDR.4,5 For instance, more than 2500 short-interfering RNA
(siRNA) patents for LC have been developed so far.6
Nevertheless, the clinical application of siRNA in combination
with other therapeutics is challenging due to the difference in
chemical and biopharmaceutical profiles. Moreover, major
obstacles to siRNA therapy arise from extracellular and intra-
cellular barriers, including (i) in vivo degradation via nucleases
(ii) inability to cross endothelial membranes and (iii) poor
efficiency of endosomal escape to reach their cytoplasmic
target. As a result, better delivery of siRNA is required in order
to drive these delicate molecules into the body and to modu-
late their fate after administration.7,8 In this context, nano-
medicine-based approaches for RNA delivery have been
explored, aiming to improve pharmacological effectiveness at
disease sites and reduce off-target effects.9–15 However, the fea-
tures of nanoparticle (NP) delivery systems need to be refined
carefully in terms of composition, structure, size, surface and
stability, and to take into account (i) the drugs to be delivered,
(ii) the characteristics of the tumor microenvironment, (iii) the
administration route and (iv) the final target.16 Current
research is focused on the design of carrier materials able to
respond to intrinsic or extrinsic stimuli (pH decrease, redox
gradients, enzyme action, light, magnetic fields, temperature,
ultrasound or electric currents) for “on demand” delivery at a
diseased site.13,17,18 In particular, by exploiting the differences
in reduction potential between normal tissues and certain
tumor microenvironments, redox-responsive NPs have been
shown to release drugs selectively at specific subcellular
locations.19 It is well-known that the cytosol, the mitochondria
and the nucleus of tumor cells are characterized by high con-
centrations of reductive glutathione (GSH) tripeptides (approx.
10 mM, about 100 to 1000 times higher than those in the
extracellular fluids and normal tissues). For this reason, GSH-
responsive NPs have been recognized as promising intracellu-
lar delivery systems for cancer and gene therapy.20
Finally, for the treatment of severe lung disorders, includ-
ing LC, administration by the pulmonary route is commonly
preferred, since it allows fast and “needle-free” direct access to
the target sites, thus reducing systemic effects. However, it is
vital to consider the anatomical and physiological features of
the lung that can prevent drug and siRNA accumulation. These
include mucociliary clearance and enzymatic barriers in the
alveolar fluid that promote siRNA degradation.21 For these
reasons, inhalable NPs for lung delivery must meet some
demanding formulation criteria.22,23
In order to develop effective inhalable NPs for pulmonary
delivery, we have focused on redox responsive NPs based on a
biodegradable and amphiphilic diblock copolymer containing
a reducible disulfide bridge between poly(lactic-co-glycolic
acid) (PLGA) and polyethylene glycol (PEG) blocks intended
for the treatment of LC. We have chosen as building blocks
PEG and PLGA, for their well-established regulatory profile
that renders our approach promising for future in vivo appli-
cations. PLGA and PEG are in fact both biodegradable and
nontoxic polymers approved by the United States Food and
Drug Administration (FDA) for medical uses.24 Moreover, this
system has previously shown (i) good ability to entrap and
trigger on-demand release of the conventional anticancer
drug docetaxel (DTX) in conditions simulating intracellular
reductive environments; (ii) high penetration properties
through an artificial mucus layer due to the presence of the
external PEG coating and (iii) enhanced uptake in 2D- and
3D- LC models due to a double (extra- and intra- cellular)
redox responsive behavior.25 For this work, the desire to co-
deliver siRNA for binary-drug therapy required modification of
the carrier by the introduction of cationic oligo-β-aminoesters
(OBAE). We chose OBAEs for their ability to condense nucleic
acids at physiological pH, protect them in their passage across
cell membranes, and enable payload release into cell interiors.
The latter can occur within acidic endosomal or lysosomal
environments, due to the presence of reversibly protonatable
amine groups and acid or base-sensitive ester bonds, which
are ultimately degraded into non-toxic small molecules.26 For
this study, we have employed a disulfide-containing OBAE,
which, as we recently reported, was able to condense siRNA
into polyplexes through a fast inkjet printing method.27 The
specific OBAE in this study was expected to protect siRNA
against biological delivery barriers but also break down intra-
cellularly to enable complete release of the nucleic acid
cargo.28,29 Through this chemical strategy, we combined the
mucus penetration properties of PEG-coated NPs,30 thus
enhancing pulmonary delivery, with functionality for nucleic
acid binding in the OBAE component, and bioresponsive
chemistries in both components encoding for site-specific
release.
We loaded NPs with DTX, clinically approved for LC treat-
ment, and a therapeutic siRNA (TUBB3-siRNA) against βIII-
tubulin, a protein involved in microtubule formation. A
growing body of preclinical and clinical data suggests that
increased expression of this protein can reduce the anti-
mitotic activity of DTX and taxanes in general,31 thus confer-
ring cancer resistance in different tumor types, including
NSCLC.32–34 Therefore, we considered that combining knock-
down of βIII-tubulin expression via siRNA with delivery of
DTX would be a potential and promising strategy to enhance
cancer cell kill with taxanes. After an in-depth evaluation of
NP behavior in LC cells, proof-of-principle for the transla-
tional potential of these NPs was explored in vivo by asses-
sing the tolerability, biodistribution and transfection of
siRNA-loaded NPs after oro-tracheal administration in an
orthotopic LC model. These studies represent the first steps
in establishing the initial safety and efficacy profiles of the
novel formulated redox-responsive NPs, in preparation for
future full combination therapy studies, in view of a potential
therapeutic alternative to the clinically used first-line lung
cancer therapy.
Results and discussion
Bioresponsive NPs were effectively derived from polymers of
PLGA and OBAE, each containing bioreducible disulfide
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bridges and with an outer PEG layer to allow good penetration
through pulmonary barriers.35 OBAEs are able to condense
siRNA and deliver it in the same cancer cell line due to its cat-
ionic charge, redox responsiveness and high buffering capacity
to allow the endosomal escape of nucleic acids. As following
step, herein we have decided to combine PLGA-block copoly-
mers with OBAEs in the same nanoplatform to: (i) ensure the
tolerability of the formulation due to the well-known safety of
PLGA and PEG polymers; (ii) exploit the mucus penetrating
properties of PEG, critical for a pulmonary administration; (iii)
load with high efficiency a siRNA for the presence of the cat-
ionic OBAE in NP core, able to induce a proton sponge effect
at cell level; (iv) load a second drug in the polymeric matrix of
NPs, in order to have a combined effect with siRNA.
Preparation and characterization of NPs
PLGA-PEG and PLGA-SS-PEG block copolymers were mixed
with cationic disulfide containing OBAE and employed to
prepare NPs which were either wholly (PLGA-SS-PEG, OBAE) or
partially (PLGA-PEG, OBAE) redox-responsive, respectively. In
particular, PLGA-based copolymers and OBAE were mixed in
the same NP in order to have a carrier with a PEG outer layer
to enhance pulmonary mucus penetration, and able to entrap
simultaneously lipophilic drugs, such as DTX, and hydrophilic
siRNA. The first drug is located in the PLGA core due its lipo-
philic profile, whereas the siRNA is entrapped through electro-
static interaction with the cationic charges of OBAE. For an
appropriate set of comparative materials, we therefore pre-
pared unloaded NPs, DTX-loaded NPs, siRNA-loaded NPs and
combined siRNA/DTX-loaded NPs.
NPs were prepared by a modified double emulsion-solvent
evaporation technique25 and characterized in terms of size,
PDI, ζ and morphology. A schematic representation of syn-
thesis of the materials and NP preparation is shown in Fig. S1
and Scheme 1, respectively. After a preliminary formulation
study by adjusting the processing parameters of the emulsifi-
cation-solvent evaporation technique, we found that the PLGA/
OBAE mass ratio 10 : 1 was the best condition to obtain NPs
with good colloidal properties and encapsulation of both DTX
and siRNA. Initially, OBAE was dissolved in EtOH and then
mixed with the DCM/PLGA solution at a volume ratio 1 : 9.
DTX was co-dissolved in the organic phase with OBAE and
PLGA-copolymers, and siRNA dissolved in the internal water
phase before the emulsification process. Composition and pro-
perties of all the formulations are reported in Table 1. The
yield for the formulations was high (∼70%) indicating that no
extensive polymer/drug precipitation or NP aggregation
occurred during preparation. The primary properties of the
PLGA-PEG and PLGA-SS-PEG formulations were similar, thus
highlighting a comparable assembling behavior of the co-
polymers. NPs displayed hydrodynamic diameters around
150 nm, with acceptable polydispersity indices and negative ζ
potential values. The spherical morphology and the absence
of NP aggregation was confirmed by TEM images (Fig. 1A).
Scheme 1 Schematic illustration of materials and NP preparation technique.


















PLGA-PEG 10 — — 75 153 ± 7 0.1 −9.9 ± 2.3 — —
DTX/PLGA-PEG 10 10 — 69 174 ± 5 0.2 −9.2 ± 4.4 6.3 ± 0.4 (71.2 ± 4.8) —
TUBB3-DTX/PLGA-PEG 10 10 0.1 65 183 ± 9 0.2 −9.7 ± 2.7 5.5 ± 1.1 (57.7 ± 8.3) 0.1 ± 0.01 (98.1 ± 1.9)
PLGA-SS-PEG 10 — — 71 143 ± 2 0.1 −11.2 ± 3.4 — —
DTX/PLGA-SS-PEG 10 10 — 70 173.0 ± 7 0.2 −12.2 ± 3.5 6.5 ± 2.4 (74.3 ± 7.1) —
TUBB3-DTX/PLGA-SS-PEG 10 10 0.1 73 178 ± 5 0.2 −8.4 ± 3.3 6.2 ± 5.1 (69.7 ± 4.5) 0.1 ± 0.03 (94.2 ± 3.3)
a Actual loading is expressed as the amount (mg) of drug encapsulated per 100 mg of NPs. b Ratio between actual and theoretical loading × 100.
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Entrapment of both drugs did not influence significantly
surface properties and ζ potentials of NPs, whereas a slight
increase of size as well as polydispersity index for both formu-
lations was observed when DTX was loaded.
However, the entrapment of siRNA in the systems did not
influence the capability of PLGA-cores to load the lipophilic
drug DTX. The complete entrapment of siRNA in all the for-
mulations was confirmed by a quantitative assay through
Nanodrop-UV measurements as well as by gel retardation
assays (Fig. S2†). In order to investigate the redox responsive-
ness of NPs in a simulated intracellular reductive environment,
different experimental techniques were performed, including
stability and release studies. As clearly evidenced in Fig. 1B,
PLGA-SS-PEG NPs showed low stability in GSH reducing media
(10 mM), highlighted by the changing of the initial particle
size and distribution curves, compared to PLGA-PEG NPs, in
line with TEM images of NPs that we have already shown in
our previous paper,36 where a strong deformation of
PLGA-SS-PEG NP structure was clearly evidenced in GSH. At
the same time, Fig. S2† evidenced a partial release of siRNA
from PLGA-SS-PEG NPs after incubation in GSH. These results
indicate the release of the surface-displayed PEG chains from
the NPs in a simulated intracellular reductive environment
through the cleavage of the disulfide bond between the PLGA
and the PEG blocks, in line with prior data from similar poly-
mers. To confirm these data, release studies of DTX from NPs
retained in dialysis membranes were carried out in the pres-
ence of GSH 10 mM in the releasing medium. In Fig. 1C, it is
possible to note that both PLGA-PEG NPs and PLGA-SS-PEG
NPs exhibited a sustained release pattern of DTX in PBS. In
particular, around 50% of the entrapped DTX was released in
14 days, compared with the free drug in the same conditions
(inset). In contrast, with the addition of GSH in the releasing
medium, complete drug release was observed from
PLGA-SS-PEG NPs after 3 days of incubation. This trend was
not significantly affected by the presence of OBAE in the for-
mulations. The same trend was found for siRNA release.
Effects of NPs in lung cancer cells
Before moving to cell studies, we tried to predict the stability
of NPs in simulated biological conditions. In fact, it is well
known that on contact with physiological fluids, some NPs will
interface with a wide range of biomacromolecules, including
proteins that can strongly modify NP colloidal properties and
identity. However, our system showed good stability in Fetal
Bovin Serum (FBS), the major protein component of cell
culture media as evident in Fig. S3,† which we attribute to the
display of PEG-chains at the NP surfaces.
A key obstacle to clinical translation of siRNA-based nano-
medicine is the extensive cytotoxicity related to many cationic
materials which have been tested, a problem which is partly
due to the limited biodegradability of commonly used polyca-
tions.37 For this reason, the ‘bioreducible nanocarrier’
approach has been developed to resolve the efficacy–toxicity
dilemma.38 However, the overall molar mass and molar mass
distribution can significantly affect the transfection activity
and cytotoxicity even of biodegradable polymers.39 We there-
fore compared the effects of free OBAE to unloaded NPs on
cell metabolic activity, as a proxy for cell viability. These experi-
ments were conducted in A549 and H1299 LC cells by the MTS
assay as described in the Experimental section. Cells were
incubated with a wide range of NP concentrations (0.05–5 mg
mL−1) and tested after 24 h of treatment. At the same time, the
effects on metabolic activity of free OBAE in the same concen-
tration range entrapped into NPs (0.005 mg–0.5 mg) was evalu-
ated. Results from MTS assays (Fig. 2A and S4†) show that 24 h
after treatment, A549 and H1299 cells retained about 90% via-
bility when treated with various concentrations of NPs as com-
pared with free OBAE. In the latter case, a higher concen-
tration dependent cytotoxicity was apparent, with a reduction
in metabolic activity of ∼80%. The reduced toxicity of the
PLGA-based NPs modified with cationic OBAE suggested that
any cationic charges in these formulations were effectively
Fig. 1 NP characterization. (A) FEG-TEM images of TUBB3-DTX/NPs;
(B) size distribution curves of NPs incubated in PBS 10 mM pH 7.4 with
or without GSH (10 mM) at 37 °C for 30 min; (C) in vitro release of DTX
and siRNA from TUBB3-DTX/NPs in PBS with or without GSH 10 mM.
Results are expressed as release% over time ± SD of three experiments.
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shielded from the cells. To highlight the safety of these
materials, NPs were tested on the same cell lines up to 50 mg
mL−1 and no toxicity was found (Fig. S5†). Subsequently, the
transfection efficiency of NPs loaded with a siRNA-based luci-
ferase knock-down sequence was assessed on luciferase-expres-
sing A549 cancer cells.
The primary properties of NPs loaded with Luc-siRNA are
reported in Table S1† and are comparable to the other for-
mulations. The silencing efficiency was evaluated after 1 h
and 4 h of NP incubation into cancer cells and compared to
untreated cells. As previously stated, we have already demon-
strated the ability of free OBAEs to deliver siRNA in cancer
cells,27 but due to the cytotoxicity of this cationic material,
we decided to not include this control in the following
experiments. For redox responsive PLGA-SS-PEG NPs, approxi-
mately 50% of silencing efficiency occurred after only 1 h of
incubation, with a slight increase over time. In contrast,
PLGA-PEG NPs showed a slower, but also time dependent,
transfection efficiency, achieving 10% and 30% of Luciferase
knockdown after 1 h and 4 h of contact time, respectively
(Fig. 2B). In Fig. S6† these results are also reported as relative
light units (RLU mg−1 protein) of Luciferase activity. This
different behavior could be attributed to the reductive trig-
gered degradation of disulfide linkages between the PLGA
and PEGylated components, leading to subsequent NP
instability and release of entrapped siRNA in the cellular
environment in a shorter time.
In order to investigate the internalization properties of NPs
into cells and to predict the fate of the drug cargoes, we
carried out uptake experiments of labeled NPs against A549
cells with subsequent confocal microscopy analysis (Fig. 2C).
For these experiments, we employed NPs loaded with a fluo-
rescent Cy™3-siRNA (properties are reported in Table S2†). As
evident in the images, the uptake of redox responsive NPs as
well as the internalization of the siRNA (red) was higher as
compared to non bioreducible NPs. This effect could be attrib-
uted to a partial extracellular responsiveness of the reducible
linkage between PLGA and PEG blocks, as previously demon-
strated25 and in line with some other studies.40,41 We sub-
sequently probed the intracellular trafficking of NPs and the
eventual endosomal escape facilitated by the cationic OBAE:
A549 cells were incubated for 4 h with Cy™3-siRNA-NPs and
then the cell nuclei and endosome were labeled with Hoechst
33258 (blue) and LysoTracker DND-26 (green), respectively. As
evident in Fig. 3, we did not observe any overlapping of the red
and green colors for both formulations, thus suggesting that
the majority of NPs or of the released siRNA escaped from the
lysosomes to the cytoplasm.
Fig. 2 (A) Cytotoxicity of unloaded NPs against A549 lung cancer cells compared to free OBAE (24 h of treatment). OBAE concentration range:
0.005–0.5 mg mL−1. (B) In vitro luciferase siRNA transfection in A549-luciferase expressing cells after different NP/cell time contact. Results are
expressed as mean ± SD of three experiments. **P < 0.01, *P < 0.05 two-way ANOVA test. (C) Confocal images of A549 cells after incubation with
Cy™3-siRNA loaded NPs (125 μg mL−1) for 4 h: (a) nucleus stained with Hoechst 33258, (b) brightfield, (c) Cy™3-siRNA emission in red (λex: 555 nm;
λem: LP 560 nm), (d) merge. Scale bar: 20 μm. Zen 2009 image Software was utilized for image processing.
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Cell metabolic activity of TUBB3 siRNA/DTX-loaded NPs
To assess the effects of DTX and of βIII-tubulin knockdown
on microtubule organization, immunofluorescence staining
of βIII-tubulin was performed in LC cells after 72 h of NP
treatment. As evident in Fig. 4 and Fig. S7,† untreated cells
(the controls of the experiments) had an intact microtubule
cytoskeleton. It is well established that microtubule bundle
formation is a hallmark of taxane exposure. The dynamic
reorganization of microtubules after treatment with docetaxel
or paclitaxel causes the inhibition of major cellular events,
and apoptosis has generally been accepted to be the predo-
minant mechanism of cell death in response to taxane
chemotherapy due to the activation of a ‘mitotic catastrophe’
by scoring of micronucleated cells and cells undergoing aber-
rant mitosis. In CLSM images, the treatment of cells with
DTX, in free form or delivered from NPs, induced strong
microtubule bundle formation in a manner not significantly
different between the delivery system employed. Concerning
the βIII-tubulin knockdown, TUBB3 siRNA in free form or
delivered from PLGA-PEG NPs did not cause any significant
modification of the microtubule networks, whereas a marked
decrease of βIII-tubulin expression was evident from siRNA
delivered from redox responsive NPs (Fig. 4). These results
were in line with the metabolic activity of cells after NP treat-
ment (Fig. 5) and the siRNA transfection properties pre-
viously discussed.
Concerning anticancer activity and effect of co-delivery, the
in vitro cytotoxicity of NPs loaded with DTX, with or without
TUBB3 siRNA, was evaluated. These MTS assays were carried
out after different time exposures (24 h and 72 h), in compari-
son to free drugs alone or in combination.
Fig. 3 Intracellular trafficking of NPs after 4 h of incubation. Plates (a–d) show PLGA-PEG NPs and plates (e–h) show PLGA-SS-PEG NPs. (a and e)
Lysotracker emission in green (λex: 488 nm; λem: SP 555), (b and f) Cy3-siRNA emission in red (λex: 555 nm; λem: LP 560), (c and g) nucleus stained
with Hoechst 33258. Images (d) and (h) show merged channels with enlarged sections contrast-enhanced for clarity. Scale bar: 20 μm. Zen 2009
image Software was utilized for image processing.
Fig. 4 Immunofluorescence microscopy of A549 cells treated with NPs
for 72 h. βIII-tubulin was stained in green whereas nuclei were stained
with Hoechst 33258 in blue. Scale bar: 10 μm. Zen 2009 image Software
was utilized for image processing.
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In Fig. 5 and S8,† the cytotoxicity as interpreted from the
loss in metabolic activity against A549 cells is reported (DTX
concentration range: 0.1–100 μg mL−1; TUBB3-siRNA concen-
tration range: 1–1000 ng mL−1). As expected, DTX, both in free
form as well as entrapped into NPs, exhibited a time- and
dose-dependent cytotoxicity due to its well-known antimitotic
mechanism of action. Furthermore, neither PLGA-PEG and
PLGA-SS-PEG NPs loaded with DTX induced statistically sig-
nificant differences in cell growth inhibition when compared
to free drug (P = 0.20).
The IC50 values of DTX against A549 cells at 72 h were cal-
culated to be around 102, 132 and 79 μg mL−1, for free DTX,
PLGA-PEG NPs and PLGA-SS-PEG NPs, respectively, with
potentiating factor values (PF) lower than 1 (Table S3†). A
similar trend was observed in H1299 cells (DTX concentration
range: 0.0001–1 μg mL−1; TUBB3-siRNA concentration range:
0.001–10 ng mL−1) (Fig. S9†). The fact that DTX-NPs showed
cytotoxicity similar to that of free DTX at the same dose is
perhaps surprising, considering that the NPs were not
expected to release all of the entrapped drug over the experi-
mental timeframe. However, as previously reported, it can be
speculated that this effect may be related to the differing
mechanisms by which DTX entered the cancer cells when
encapsulated in NPs. Thus endocytic transport of NPs would
be expected to reduce the interaction of DTX with extracellular
proteins in the cell culture media, and also bypass any mem-
brane-associated DTX efflux pumps.42–44 In addition, the
encapsulation and co-delivery of TUBB3-siRNA into biorespon-
sive NPs appeared to potentiate the anti-proliferative activity of
DTX, especially in A549 cells which were otherwise less sensi-
tive to DTX activity. Specifically, the IC50 values of
PLGA-SS-PEG NPs notably decreased after 72 h (6.5 μg mL−1 in
A549 cells), reaching PF values of 16 and 12 vs. free DTX and
the corresponding bioreducible formulation loaded with only
DTX, respectively. This different potentiation compared to
non-responsive NPs indicated a clear DTX/TUBB3 synergistic
activity, in line with the much higher efficacy of this
formulation.
In vivo assays to assess potential of NPs for drug delivery after
inhalation
On the basis of the above encouraging data for delivery and
efficacy in cancer cell lines, we moved to preliminary in vivo
studies. The aim of these experiments was to evaluate if the
developed NPs were able to exert their silencing effect follow-
ing pulmonary administration. To facilitate the study, we
decided to look at an orthotopic model of lung cancer in mice
established with luciferase-expressing cancer cells. siRNAs for
the knock-down of luciferase activity are also readily available.
These assays were expected to yield the key proof-of-principle
that a biological target could be targeted by the NPs in an
in vivo cancer setting, but without the complexities involved in
evaluating the overall tumor response. In particular, since the
combination of DTX and anti-TUBB3 therapies in NP formu-
lations would require significant number of controls (single
drugs NPs, free drugs, combinations) and thus of animals, it
was essential for ethical reasons to carry out pilot experiments
in as few mice as possible. Therefore, we applied anti-luc
siRNA-containing NPs via intra-tracheal administration in an
A549-luc bioluminescent orthotopic LC model, and assessed
tolerability and biodistribution of the formulations, as well as
transfection efficiency in the knock-down of luciferase.
Tumors spontaneously grew in the lungs following intrave-
nous injection of A549-luc tumor cells in the mice. Tumor
growth and the effects of treatments were monitored by whole
body in vivo bioluminescent imaging (IVIS) and confirmed by
X-ray imaging (Fig. S10†). Data are presented in terms of mean
tumor bioluminescent intensity (BLI) and typical IVIS images
from one animal representative of each treatment group at
each time point. Prior to the treatment with therapeutic NPs,
acute tolerability of NPs loaded with a scrambled siRNA and
without DTX was assessed in tumor bearing mice (three mice
per treatment under dosing as per the therapy study for 14
days, followed by cessation of dosing and observation for a
further 14 days). The properties of the NPs used in these
experiments are reported in Table S4,† and as control a free
Fig. 5 Cell metabolic activity of PLGA-PEG NPs and PLGA-SS-PEG NPs
toward A549 cells after 72 h of incubation. Results are expressed as
mean ± SD of three experiments. ***P < 0.001, **P < 0.01, *P < 0.05 free
DTX, two-way ANOVA test.
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scrambled siRNA at the same concentration was used. No
adverse effects were noted in the mice (data not shown).
To assess NP biodistribution after intratracheal adminis-
tration, tumor-bearing mice were randomized in 2 groups of
3 mice (n = 6). NPs loaded with the red fluorescent model drug
DiR (DIR/PLGA-PEG NPs and DIR/PLGA-SS-PEG) were adminis-
tered intratracheally and fluorescence images were collected
live after 1 h and 24 h as well as after animal sacrifice by IVIS.
The accumulation of DiR into the tumors after 1 h was higher
in the case of PLGA-SS-PEG NPs with a more symmetrical dis-
tribution in the lungs (Fig. 6A and B). However, after 24 h, DiR
fluorescence into the lungs strongly decreased compared to
the control formulation, probably due to the redox responsive-
ness of the system that favours DiR release in the reductive
tumor environment. These results are confirmed also by
ex vivo analysis of the organs from sacrificed mice (Fig. 6C).
After 24 h of treatment with NPs, DiR fluorescence was
retained in the lungs (Fig. S11†), but fluorescence was found
also in other organs (e.g. kidney and brain) only in the case of
PLGA-SS-PEG formulation, which suggests again that DiR
release from redox-responsive NPs was higher than that from
PLGA-PEG NPs (Fig. S12†), as observed in the in vitro study.
Finally, to evaluate the ability of the NPs to deliver siRNA
into the lung, gene silencing efficacy studies were carried out.
Two weeks after tumor initiation, mice were treated with NPs
loaded with a siRNA against Luciferase (antiLuc-siRNA) or
with a scrambled siRNA (ctr-NPs). Mice were dosed again intra-
tracheally and after 72 h, luminescence of the tumors was
monitored in vivo as well as ex vivo. A reduction of lung bio-
luminescence after treatment with PLGA-SS-PEG and
PLGA-PEG NPs (Fig. 7A). Moreover, the effect of anti-Luc-
siRNA NPs was confirmed through the analysis of excised
lungs after 72 h. The data showed that bioluminescence of the
lungs strongly decreased compared to those treated with NPs
loaded with a scrambled siRNA as control (Fig. 7B), thus
demonstrating the efficacy of this system to reduce the lung
tumor.
These preliminary data established the principle of deliver-
ing functional payloads to the lungs via combined
PLGA-SS-PEG and OBAE NPs. The use of DiR as a fluorescent
payload indirectly evaluated the efficiency of the NPs to release
a small hydrophobic molecule such as DTX. Fluorescence
from DiR was observed throughout the lungs within 1 h from
both PLGA-PEG and the PLGA-SS-PEG formulations, indicating
successful transport of the formulations, while the more rapid
loss of the DiR signal in the lungs from the PLGA-SS-PEG NPs
compared to the non-redox responsive variant implied a faster
release of the payload across the lungs and into systemic circu-
lation. The end-fate organ accumulation data showed that DiR
was present mostly in the liver and kidneys at 24 h, as expected
for small molecule transport, but were also indicative that for
subsequent experiments relating to DTX delivery, some formu-
lation tuning would be required to sustain release in the lungs
and delay passage through to systemic circulation. For the
siRNA delivery assays, the data showed effective knockdown of
luciferase from the constitutively expressing A549 luc cells
after 72 h for both formulations.
Fig. 6 (A) Ex vivo fluorescence images and (B) quantification of the mean fluorescent intensity of DiR in excised lungs of the A549-luc tumor-
bearing mice after 1 h and 24 h of treatment with DiR-loaded NPs; (C) quantitative presentation of organ biodistribution ex vivo at 24 h.
Fig. 7 (A) Ex vivo bioluminescence images and (B) quantitative lumine-
scence of excised lungs of the A549-luc tumor-bearing mice after 72 h
of treatment with NPs loaded with a siRNA against Luciferase. ***P <
0.001 vs. ctr-NPs, two-way ANOVA test.
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When considered together, cell culture and preliminary
in vivo experiments demonstrated both the promise and
complexity in using combined NPs. The cell data clearly
demonstrated a combined effect of DTX and TUBB3 siRNA
in LC cells, and indicated that the PLGA-SS-PEG redox-
responsive formulation was the most effective. For the
orthotopic lung cancers in mice, successful delivery of both
a small molecule dye and a siRNA was demonstrated, with
effective knockdown of luciferase showing that NPs were
able to cross tissue and intracellular barriers to release an
active biological cargo. However, the differences in the for-
mulations were less apparent in the in vivo model, which
may have related to the intricacies in transport of small
and large molecules in lung tissue, and the impact of
redox-responsiveness on dye/drug effective dose accumulat-
ing in cancer cells. There is an imperative to evaluate differ-
ential organ accumulation of these drugs when delivered
in vivo as well as to establish routes to control release rates
for each therapeutic from combination NPs. These ques-
tions are now under evaluation and will be reported
subsequently.
Conclusions
Here we have reported novel redox-responsive PEGylated
NPs, with the aim to deliver simultaneously into the lung
the conventional anticancer drug docetaxel and a therapeutic
siRNA against βIII-tubulin (TUBB3 siRNA). Both drugs were
loaded inside the carrier and showed a complete and fast
release at simulated intracellular levels of reductive agents.
The redox-responsiveness of these systems led to higher
silencing efficiency of delivered siRNA and cell uptake, in
comparison to non-redox-responsive variant. Concerning
anticancer activity, the co-delivery of TUBB3 siRNA through
bioresponsive nanoparticles strongly increased DTX cyto-
toxicity in lung cancer cells, thus highlighting the effective
combined anticancer activity of the compounds. In vivo,
these systems were well tolerated after intratracheal adminis-
tration in a bioluminescent A549-luc lung cancer model. The
suitability of the system for inhalation delivery was also
demonstrated, with data showing that NPs reached the lungs
where an anti-Luc siRNA was released and exerted its silen-
cing activity. These results indicate that combining DTX
with TUBB3 siRNA in redox-responsive NPs as we have
shown here could lead to promising candidates for the local
and combined therapy of lung cancer with a specific final




All solvents were of analytical or HPLC grade and purchased
from Sigma or Fisher Scientific unless otherwise stated.
Deuterated solvents, the two monomers glycolide (GL) and DL-
lactide (LA) were from Sigma. Poly(ethylene glycol) methyl
ether (mPEG) and α-methoxy-ω-amino poly(ethylene glycol)
(mPEG-NH2) with Mn = 2.0 kDa were purchased from Iris
Biotech GmbH (Germany). Dialysis membrane (MWCO 3500,
regenerated cellulose) was used as received from Spectrapor.
Tin(II)-2-ethylhexanoate (SnOct2), acryloyl chloride, ethylene-
dioxy-bis-ethylamine, triethylamine (TEA), dithiodiethanol,
Tris-Acetate-EDTA (TAE) buffer, poly(vinyl alcohol) (PVA,
Mowiol®40–88, Mw ∼ 31 000), sodium chloride, potassium
phosphate dibasic and potassium phosphate monobasic,
sodium azide, magnesium chloride, potassium chloride,
sodium phosphate dibasic, sodium sulfate, calcium chloride
dehydrated, sodium acetate, sodium bicarbonate, sodium
citrate dehydrate, ethidium bromide, Hoechst 33258, BCA
reagent, glutathione (GSH), were used as received from
Sigma Aldrich. Docetaxel (DTX, MW = 807.88) was purchased
from LC laboratories (USA). 1,1′-Dioctadecyl-3,3,3′,3′-tetra-
methylindotricarbocyanine Iodide (DiR) was acquired by
Thermo Fisher Scientific (UK). siRNA against Luciferase
(Luc-siRNA) (CCGCAAGAUCCGCGAGAUU), scrambled siRNA,
Silencer®Cy™3 labeled Negative Control (λex max = 547, λem =
563 nm) and siRNA against βIII-tubulin (TUBB3-siRNA)
(GUACGUGCCUCGAGCCAUUUU) were provided by Eurogentec
(UK). Luciferase Assay System and CellTiter 96® AQueous One
Solution Cell Proliferation Assay (MTS) were provided by
Promega (UK).
Synthesis of PLGA block copolymers and OBAE
Synthesis of PLGA-PEG block copolymer. PLGA-PEG diblock
copolymer was prepared as previously described.25 Briefly,
mPEO2000-OH and Sn(Oct)2 were used as initiator and catalyst,
respectively, in the bulk ring-opening polymerization (ROP) of
DL-lactide (LA) and glycolide (GL) at 130 °C; LA/GL/initiator
molar ratio = 25 (Mn = 8.3 kDa at 25 °C in chloroform; Đ = 1.2;
yield = 86%).
Synthesis of PLGA-SS-PEG block copolymer. A redox respon-
sive PLGA-SS-PEG diblock copolymer was prepared as pre-
viously described25 via a three-step reaction, i.e. the synthesis
of 2-((hydroxymethyl)disulfanyl)ethyl acrylate (SS), (2) the syn-
thesis of a PLGA-S-S-ethyl acrylate (PLGA-SS) and (3) the
Michael addition reaction between PLGA-SS and mPEG2000-
NH2. Briefly, the ROP initiator 2-((hydroxymethyl)disulfanyl)
ethyl acrylate (2HMDEA) was prepared by reacting dithio-
diethanol with acryloyl chloride through a published method
with minor modifications.45 Then, 2HMDEA and Sn(Oct)2 were
used as initiator and catalyst, respectively, in the bulk ROP of
DL-lactide (LA) and glycolide (GL) at 130 °C; finally,
PLGA-SS-PEG diblock copolymer was synthesized by aza-
Michael Addition between the amino group of mPEG2000-NH2
and the acrylic end group of PLGA-SS at 65 °C for 6 days. LA/
GL/PEG molar ratio = 25 (Mn = 9.6 kDa at 25 °C in chloroform;
Đ = 1.2; yield = 70%).
Synthesis of OBAE. The synthesis of the oligo-β-aminoester
(OBAE) was via a two-step reaction, i.e. the synthesis of di-
sulfide-based diacrylate (DSD) and (2) the Michael addition
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reaction between DSD and ethylenedioxy-bis-ethylamine.
Synthesis of DSD was carried out through a literature method
with minor modifications.45 Then, for the Michael Addition
reaction, DSD was mixed with ethylenedioxy-bis-ethylamine
(molar ratio 1 : 1.5) in DCM in the dark at 30 °C for 5 days
under nitrogen. (Mn = 2.1 kDa at 25 °C in DMF; Đ = 1.2; yield =
72%).
1H- and 13C NMR, FTIR spectra, size exclusion chromato-
graphy (SEC) measurements and differential scanning calori-
metry (DSC) of both PLGA-based copolymers as well as OBAE
were performed as previously reported.25
Preparation and characterization of NPs
Preparation of NPs. PLGA-PEG and PLGA-SS-PEG were mixed
with OBAE and employed to prepare NPs by a modified emul-
sion-solvent evaporation technique. DTX as lipophilic anti-
cancer drug model and a siRNA (scrambled or against βIII-
tubulin) were loaded into NPs at 10% w/w and 0.1% w/w,
respectively. Briefly, 1 mg of OBAE was solubilized in 0.1 mL of
EtOH and then mixed to a DCM solution (0.9 mL) containing
the PLGA-based copolymer (10 mg) and DTX (1 mg).
Thereafter, 0.1 mL of an internal water phase containing 10 μg
of siRNA (0.8 nmol) were added to the organic phase and the
mixture was sonicated for 1 min at 3 W (Ultrasonic Sonopuls
HD 3200, Bandelin, UK) using a microtipe probe. This first
emulsion was poured in water (10 mL) in the presence of PVA
0.5% w/v, and sonicated again for 5 min at 3 W. Thereafter,
the organic solvent was evaporated by mechanical stirring (300
rpm) for 3 h at r. t. and then filtered (0.45 μm). NPs were then
collected by centrifugation (14 000 rpm, 30 min, 4 °C) after
washing twice with distillated water to remove the excess of
PVA and the unloaded drugs. Finally, NPs were re-dispersed in
water (1 mL), freeze-dried for 24 h and kept at 4 °C. Unloaded
and NPs loaded with a single drug were also prepared as con-
trols. Recovery yield of production process was evaluated by
weighing the solid residue after freeze-drying. Results are
expressed as the ratio of the actual NPs mass to the theoretical
polymer mass × 100.
Colloidal properties of NPs. Hydrodynamic diameters (DH),
polydispersity indices (PDI) and zeta potentials (ζ) of NPs were
determined on a Zetasizer Nano ZS (Malvern Instruments Ltd).
Results are reported as mean of three separate measurements
of three different batches (n = 9) ± standard deviation (SD).
The morphology of the NPs was examined by transmission
electron microscopy (TEM). Samples were imaged using a
JEOL 2100F FEG-TEM electron microscope. A few drops were
added onto a copper grid and allowed to dry in air. NPs were
negatively stained with 2% phosphotungstic acid solution.
DTX and siRNA loading. DTX loading inside NPs was
assessed by dissolving 1 mg of freeze-dried NPs in 1 mL of
THF under stirring for 1 h. Thereafter the sample was filtered
through a 0.22 μm filter and analyzed for DTX content by
HPLC on a Shimadzu apparatus equipped with a LC-10ADvp
pump, a SIL-10ADvp autoinjector, a SPD-10Avp UV-Vis detector
and a C-R6 integrator. The analysis was performed on a ACE
5μm, C18 column (250 × 4.6 mm, Å) (Phenomenex, USA). The
mobile phase was a 40 : 60 (v/v) mixture of 20 mM phosphate
buffer at pH 4.5 and acetonitrile pumped at a flow rate of 1 mL
min−1. The UV detector was set at 227 nm. A calibration curve
for DTX in THF was constructed in the concentration range
1–200 µg mL−1.
The loading of siRNA was confirmed by agarose gel retar-
dation assays. 1 mg of NPs containing 1 μg of siRNA were
loaded on 2% agarose gel in Tris-Acetate-EDTA (TAE) buffer
and subjected to electrophoresis for 45 min at 70 V. siRNA
bands were stained with ethidium bromide and finally visual-
ized with an UV illuminator. The entrapment efficiency of
siRNA was assessed by dissolving 1 mg of freeze dried NPs in
500 μL of DCM under stirring for 1 h. Thereafter, 500 μL of
water were added and the sample stirred for 1 h further. After
centrifugation at 5000 rpm for 10 min, the aqueous phase was
collected and analysed by UV spectrophotometry (Nanodrop
2000 spectrophotometer, Thermo Scientific, UK) at 290 nm.
Potential interference of the polymers and DTX on siRNA
absorbance was preliminary assessed spiking a siRNA solution
in water with different amount of DTX-loaded NPs.
Redox responsiveness of NPs. To determine the stability of
NPs under intracellular reductive conditions, gel retardation
assay and size measurements of NPs dispersed in PBS pH 7.4
(1.5 mg mL−1) enriched with GSH 10 mM were taken after
incubation at 37 °C for 30 min.
In vitro release of DTX in PBS with or without GSH 10 mM
was investigated by a dialysis method. 2 mg of NPs were dis-
persed in 0.5 mL of PBS solution and placed in a dialysis bag
(MWCO = 3500 Da, Spectra/Por®). The sample was plunged in
8 mL of PBS (sink condition) and kept at 37 °C. At selected time
intervals, 1 mL of release medium was withdrawn and replaced
with an equal volume of fresh medium. DTX quantitative ana-
lysis was performed by HPLC as described above. Release
profile of the free drug is reported for comparison. Results are
expressed as release% over time ± SD of three experiments.
For siRNA release studies, 500 μL of NP dispersions were
diluted with PBS at pH 7.4 with or without GSH 20 mM to a
total volume of 1 mL and incubated at 37 °C. At different time
points aliquots of 500 μl of NP dispersions were collected and
centrifuged at 16 000g for 30 min at 4 °C. The supernatants
were collected and analysed at 280 nm by UV-vis spectrometry
(NanoDrop™ 2000). The values were calculated as mean ± SD
of three experiments.
NP stability in protein-rich media. To determine the stability
of NPs in simulated biological conditions, a known amount of
NPs (0.5 mg) was dispersed in PBS 10 mM pH 7.4 with or
without Fetal Bovine Serum at 10% and incubated at 37 °C for
different times. Size measurements of the samples were taken
by dynamic light scattering on a Zetasizer along time up to
48 h of incubation.
Cell studies
Cell culture. H1299 and A549 lung cancer cell lines were pur-
chased from the American Type Culture Collection (USA).
H1299 cells were cultured in RPMI-1640 medium sup-
plemented with 10% v/v fetal bovine serum (FBS), 1.5 mM
Paper Nanoscale
























































































L-glutamine, 100 units ml−1 penicillin, and 100 μg ml−1 strep-
tomycin under humidified atmosphere of 5% CO2 at 37 °C.
A549 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM), supplemented as above.
Effects of OBAE on cell metabolic activity. The cytotoxicity of
cationic OBAE entrapped inside NPs was inferred through the
MTS assay. Cells (2 × 104) were placed in 96-well plates and cul-
tured in 200 μL of cell medium with FBS at 10%. After 24 h,
cells were treated with unloaded NPs (from 0.05 to 5 mg mL−1)
and free OBAE in the same concentration range theoretically
entrapped into NPs (0.005–0.5 mg mL−1). Cells treated with
0.1% (v/v) Triton-X 100 and fresh media were used as a positive
and a negative control, respectively. After different incubation
times up to 24 h, cells were washed with PBS and treated with
CellTiter 96® Aqueous One Solution Cell Proliferation Assay
(20 μL per well). After further incubation (3 h), the absorbance
was read at 490 nm in a microplate reader (Tecan Platereader).
Transfection studies. For transfection studies, A549 luci-
ferase expressing cells (5 × 104) were seeded into 24-well plates
and cultured in 500 μL of cell medium with FBS at 10%. After
24 h, the culture medium was replaced with 0.5 mL of fresh
medium and treated with NPs loaded with a siRNA against
luciferase (1 μg of Luc-siRNA per well). After different incu-
bation times (1 h and 4 h), cells were washed in order to
remove NPs and incubated again at 37 °C until 48 h. Finally,
after transfection, luciferase activity was measured as RLU
mg−1 protein using a luciferase assay system and BCA reagent.
Uptake and intracellular trafficking of NPs. A549 cells were
used to assess the internalization and the intracellular traffick-
ing of NPs loaded with a fluorescent Cy™3-siRNA (0.1% w/w).
Cells were seeded into 24-well/plates (2 × 105 cells per well) in
0.5 mL of DMEM with 10% FBS. After 24 h, cells were washed
and incubated for 4 h with 125 µg mL−1 of NPs, freshly re-sus-
pended in milli Q water and diluted in medium without 10%
of FBS. After incubation with NPs, the cells were washed and
fixed in ice-cold PBS with 2% p-formaldehyde for 10 min fol-
lowed by adding Hoechst 33258 (1 μg mL−1) and LysoTracker
Green (100 nM). Red fluorescence of Cy™3-siRNA, blue fluo-
rescence of Hoechst 33258 and green fluorescence of
LysoTracker Green were observed using a Zeiss LSM 700
Confocal Laser Scanning Microscope (CLSM) equipped with
Argon (488 nm) and HeNe (561, 639 nm) lasers and a 40X/1.2
NA water objective. Images were acquired with λex 555 nm and
spectral filters of LP 560 nm for Cy™3-siRNA detection. Zen
2009 image Software was utilized for image processing.
Immunofluorescence. Cells (1.5 × 105) were placed in 24-well
plates and cultured in 0.5 mL of cell medium with FBS at 10%.
After 24 h, cells were treated with free drugs, DTX-NPs, TUBB3-
NPs and TUBB3/DTX-NPs. DTX and siRNA concentrations were
respectively 2.5 μg mL−1 and 0.25 μg mL−1 for H1299 cells,
25 μg mL−1 and 2.5 μg mL−1 for A549 cells. After 72 h of treat-
ment, cells were washed and fixed in ice-cold PBS with 2%
p-formaldehyde for 10 min. Then, cells were permeabilized
with TritonX-100 (0.1%) in PBS for 20 min at r.t. and treated
with an Anti-III-tubulin human antibody (Abcam, UK) followed
by the secondary antibody Rhodamine Red goat anti-mouse
IgG (Invitrogen, UK). Finally, nuclei were stained with Hoechst
33258 (1 μg mL−1) for an additional 15 min. Cells were
observed by CLSM.
Cell metabolic activity of TUBB3 siRNA/DTX-loaded NPs.
Cells (2 × 104) were placed in 96-well plates and cultured in
0.2 mL of cell medium with FBS at 10%. After 24 h, cells were
treated with DTX-NPs (NPs loaded with DTX), TUBB3-NPs (NPs
loaded with TUBB3-siRNA), TUBB3/DTX-NPs (NPs loaded with
both drugs) and free drugs alone and in combination. DTX
and siRNA concentration ranges were set respectively at
0.0001–1 μg mL−1 and 0.001–10 ng mL−1 for H1299 cells, and
at 0.1–100 μg mL−1 and 1–1000 ng mL−1 for A549 cell line.
DMSO 0.1% (v/v) was used as vehicle for free DTX. After 24 h
and 72 h, cell viability was assessed through MTS assay as
described above.
Statistical analysis. Experimental data were expressed as
means ± standard deviation (SD). Each value was the mean of
at least three repeat experiments in each group. Normal distri-
bution was assumed and data therefore tested using para-
metric tests. The statistical significance between two groups
was analyzed by Student t-test. Differences with P < 0.05(*) or P
< 0.01(**) were considered statistically significant. The differ-
ence between three or more groups was analyzed by one-way
analysis of variance (ANOVA) multiple comparisons.
In vivo studies
Animals. Animal studies were conducted under the UK
Home Office Licence (PPL P435A9CF8 protocol 11), NCRI
guidelines for the welfare and use of animals in cancer
research, LASA good practice guidelines and FELASA working
group on pain and distress guidelines. All animal procedures
were performed in accordance with the Guidelines for Care
and Use of Laboratory Animals of Nottingham University and
approved by the University’s Animal Welfare and Ethical
Review Body. 32 female CD-1 Nu mice were purchased from
Charles River Laboratories (UK) and acclimatized for a week
prior to study set up. Mice were maintained in IVCs
(Tecniplast, UK) within a barrier unit illuminated by fluo-
rescent lights set to give a 12 h light–dark cycle (on 07.00, off
19.00), as recommended in the UK Home Office Animals
(Scientific Procedures) Act 1986. The room was air-conditioned
by a system designed to maintain an air temperature range of
21 ± 2 °C and a humidity of 55% + 10%. Mice were housed in
social groups during the procedure with irradiated bedding
and provided with autoclaved nesting materials and environ-
mental enrichment. Sterile irradiated 5 V5R rodent diet (IPS
Ltd, UK) and autoclaved water was offered ad libitum.
Tumor establishment and dosing. Tumors in the mice were
initiated by an approved S1 method as follows. A549-luc tumor
cells were suspended in a standard formulation of Matrigel (2
× 106 cells) and the cell suspension was drawn into a 1 ml
syringe. An aliquot (50 μl) of the cell suspension was then
injected intravenously into the tail vein of non-anaesthetised
mice, after warming the animal in a purpose-built thermostati-
cally controlled warming unit. Tumor establishment and
growth was monitored by bioluminescence imaging to assess
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tumor burden prior to recruitment into the different studies
through an IVIS Spectrum weekly, and at termination, to
provide an optical post mortem. Tumor measurements and 3D
image reconstruction were made using Living Image (4.3.1
build) software (Caliper Life Sciences Hopkinton, MA, USA). To
quantify the fluorescence intensity, a fluorescence calibrated
unit (termed radiant efficiency), representing the fractional
ratio of emitted photons per incident excitation photon, was
used to compensate for non-uniform excitation light patterns.
Dosing was initiated in established tumors (mice six to
seven weeks old), those whose volume was demonstrably larger
than the original implantation volume. Mice were anesthetized
with 10 ml g−1 ketamine/medatomidine (Ket 0.9 ml/Met
0.3 ml/NaCl 8.8 ml), restrained on a support ring and dosed
intratracheally by a Microsprayer Aerosolizer (Model IA-IC,
PennCentury, Philadelphia, PA, USA) (50 μL per dose). The
administration was guided by a pediatric otoscope. All animals
were sacrificed when tumor volume reached the maximum
permissible size of 1.5 cm diameter in at least one mouse.
Tolerability study. In order to check the safety of the carrier,
tolerability studies on tumor-bearing mice were performed.
NPs loaded with a scrambled siRNA were intratracheally admi-
nistered (50 μL of 10 mg mL−1 NP dispersion) by the
Microsprayer Aerosolizer. Survival and tumor growth was
monitored up to 21 days after administration.
Biodistribution studies. The biodistribution of NPs in
tumor-bearing mice was assessed employing NPs loaded with
DiR red fluorescent dye (1% w/w). Mice were dosed intratrache-
ally with DiR/PLGA-PEG NPs or DiR/PLGA-SS-PEG NPs (3 mice
per group). Each dose contained 10 μg of DiR in 50 μL. The
evaluation of biodistribution was carried out at 1 h and 24 h
term. Imaging of mice on front and back was carried out in
the IVIS Spectrum with parameters chosen for DiR detection
and the closest red-shifted filter set. Imaging filters were
selected from 710/780 (plus 430ex controls). A ‘blue light’
control filter set was also used to provide auto-fluorescence
data for un-mixing and image analysis. For the lung IVIS ana-
lysis, mice were culled by an approved S1 method post initial
imaging, while still under anesthetic; all mice organs were dis-
sected and imaged (kidney, 25 μl urine, liver, spleen/pancreas,
lung, heart, bladder, brain, lymph nodes-Inguinal). The ex vivo
fluorescent images of the major organs were also detected
with the same imaging system as described above.
siRNA gene knockdown efficacy studies. At a time period of
2 weeks after tumour initiation, mice were treated with fluo-
rescent NPs loaded with DiR (1% w/w) and a Luc-siRNA
(0.1% w/w). Mice were randomly allocated to different
groups: (1) Luc-siRNA-DiR/PLGA-PEG NPs (2) Luc-siRNA-DIR/
PLGA-SS-PEG NPs and (3) scrambled-siRNA-DiR/PLGA-SS-PEG
NPs (n = 9). Mice were intratracheally dosed (5 μg of siRNA in
50 μl per dose) as described above. At 1, 24 and 72 h after treat-
ment, DiR distribution was monitored via fluorescence
imaging, whereas tumors by bioluminescent imaging. The
signal intensity of tumors was quantified as the sum of all
detected photon counts within the ROI. At 72 h the mice were
sacrificed and the resected lungs imaged.
Statistical analysis. GraphPad Prism 7 software (La Jolla, CA,
USA) was used for data analysis. Comparisons between two
groups were made using independent samples Student’s t-test
and one way analysis of variance (ANOVA) was applied for the
comparison of three or more groups. Tukey’s multiple com-
parison test (post-hoc) was used in conjunction with ANOVA to
evaluate differences in individual means in EGFR staining
data. For other experiments, Bonferroni post-hoc test was
applied for comparison of group means of three or more
groups. p values of <.05 were considered statistically signifi-
cant. *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001,
and p < 0.0001, respectively.
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